Know2eat

Benfotiamine

Vitamins

What benfotiamine may help with

Ranked by how strong the human evidence is — best supported first.

Best supportedBlood glucose responseNot enough evidence· 3 sources

Then, in order

4 things to know first — allergies, interactions and limits

About Benfotiamine

A synthetic lipid-soluble derivative of thiamine, developed in Japan and licensed as a medicine in parts of Europe. It bypasses the saturable transporter that limits ordinary thiamine absorption, producing substantially higher blood and tissue thiamine levels.

Benfotiamine is a rare case of a supplement whose absorption advantage is real and measured — blood thiamine levels reach several times those achieved by equivalent oral thiamine. What it does with that advantage is much less clear. It has been studied mainly in diabetic neuropathy and nephropathy on the theory that thiamine derivatives suppress glucose-driven damage pathways, and results have been mixed: some short trials report symptom improvement, a well-conducted trial in diabetic nephropathy found no benefit on kidney markers, and a longer neuropathy trial was negative. It is sold in Germany as a drug for polyneuropathy and in the US as a supplement.

Sold as
Tablet, Capsule, Prescription preparation (parts of Europe), Combination with other B vitamins
Also known as
S-benzoylthiamine O-monophosphate, Fat-soluble thiamine, Lipid-soluble B1

Regulation: A licensed medicine for polyneuropathy in Germany and some other European countries; a dietary supplement in the US with no pre-market efficacy review. No Tolerable Upper Intake Level exists for thiamine or its derivatives.

What the research used

The amounts, forms and durations published trials of Benfotiamine actually administered.

These are the amounts published trials administered — not a recommendation, and not a dose to copy. Trial participants were screened, supervised and given a characterised preparation. What is in a retail bottle is frequently not what was studied, and the amount that suits one person is not general advice.

  • Studied for Diabetic polyneuropathy trials

    300–600 mg

    Limited

    Tablet, in divided doses · 6 weeks

    The larger dose performed better than the smaller in one dose-finding trial, but the studies are short, small and mostly from a small number of European centres, several with manufacturer involvement.

  • Studied for Diabetic nephropathy trial

    900 mg

    Moderate

    Tablet, daily · 12 weeks

    This trial found no improvement in urinary albumin excretion despite a large rise in blood thiamine — an important negative result for the mechanism.

This is general information about food, not medical advice. It cannot diagnose, treat or replace guidance from a clinician who knows your history.

When it was taken

Each window says whether a trial compared it against an alternative, or whether it is convention and pharmacology. Most timing advice is the second kind.

None of the timings below were directly compared in a trial. They reflect how the research happened to dose, or what the pharmacology implies — which is not the same as a timing being better.

  • With food

    Not enough

    Usually dosed with meals in trials, and split across the day. Whether this matters for absorption has not been separately tested.

    Timing was not directly compared. This reflects convention or how the compound behaves in the body, not a trial showing this window works better.

The evidence in depth

Best supported: Not enough

What each association actually rests on, and the papers behind it. A rating describes the state of the research, not how promising the supplement sounds. How we rate evidence.

Blood glucose response

Blood Sugar & Metabolic Health
Not enough evidence

Benfotiamine does not lower blood glucose. The hypothesis is that it reduces glucose-driven tissue damage independently of glycaemic control, and the trials testing that on kidney markers were negative.

What may be going on: Raised transketolase activity is proposed to divert glycolytic intermediates away from pathways that generate advanced glycation end products. The mechanism is well described in laboratory work and has not delivered in clinical endpoints.

Not enough evidence. Not enough human research to say anything useful yet.

View the 3 sources

Deep research mode adds each paper’s own conclusion and stated limitations.

Joint comfort

Joint Health
Not enough evidence

Some short trials in diabetic polyneuropathy report reduced pain scores, but the outcome is nerve pain rather than joint pain, the trials are small and short, and a longer trial was negative.

Not enough evidence. Not enough human research to say anything useful yet.

View the 3 sources

Deep research mode adds each paper’s own conclusion and stated limitations.

Things to know

Interactions, contraindications and dose limits, most serious first. Concentrated extracts interact with medication in ways the whole plant does not, so this section carries more weight here than it does on a food page.

  • Worth knowing

    Not a substitute for diabetes care

    Benfotiamine does not affect blood glucose, blood pressure or lipids, which are the modifiable drivers of diabetic complications. Using it in place of glycaemic control is the substantive risk attached to the product.

  • Worth knowing

    Long-term safety is unquantified

    Trials run six to twelve weeks at doses producing tissue thiamine levels far above anything achievable from food. There is no long-term safety data at these exposures, and no upper limit exists to reference.

  • Worth knowing

    Not the same as thiamine for deficiency management

    Benfotiamine raises thiamine status effectively, but the established protocols for Wernicke encephalopathy and severe deficiency use parenteral thiamine in hospital. Substituting a supplement in that situation is dangerous.

  • Worth knowing

    Sulphur odour and gastrointestinal upset

    Benfotiamine tablets often carry a sulphurous smell, and mild nausea or stomach upset is the most commonly reported side effect in trials.

Evidence ratings on this page: 2 not enough evidence.

Supplements are sold in the US without pre-market review of efficacy or safety. Nothing on this page is a recommendation to take Benfotiamine, or a dose to follow.